SF
CBAY

Synovus Financial’s Cymabay Therapeutics CBAY Stock Holding History

Synovus Financial’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-233
Closed -$1K – 1525
2020
Q2 		$1K Hold
233
– – ﹤0.01% 1539
2020
Q1 		$0 Hold
233
– – ﹤0.01% 2247
2019
Q4 		$0 Hold
233
– – ﹤0.01% 1603
2019
Q3 		$1K Hold
233
– – ﹤0.01% 1434
2019
Q2 		$2K Hold
233
– – ﹤0.01% 1331
2019
Q1 		$3K Hold
233
– – ﹤0.01% 1321
2018
Q4 		$2K Hold
233
– – ﹤0.01% 1337
2018
Q3 		$3K Buy
+233
New +$2.89K ﹤0.01% 1311

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Synovus Financial's CBAY Position: Q3 2020 in Review

Synovus Financial sold out of Cymabay Therapeutics (CBAY) in Q3 2020, closing a stake of 233 shares — an estimated $1K sold.

Synovus Financial first reported a position in CBAY in Q3 2018 and held it in 8 quarters. The position peaked at $3K in Q1 2019. 120 funds tracked by Wall St. Rank hold CBAY as of Q3 2020.

  • Synovus Financial reported no remaining Cymabay Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Synovus Financial sold 233 Cymabay Therapeutics shares in Q3 2020, an estimated $1K.
  • Synovus Financial first reported a position in Cymabay Therapeutics in Q3 2018 and held it in 8 quarters.
  • Synovus Financial's Cymabay Therapeutics position peaked at $3K in Q1 2019.
  • 120 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.